Alemtuzumab treatment in Denmark

Asta Theodorsdottir prsent data from the The Danish Multiple Sclerosis Registry about the demographics of the alemtuzumab-treated population in Denmark; the treatment strategy; the number of cycles and its relation to previous disease modifying treatments (DMTs); and the frequency of switch to other DMTs.

In this MEDtalk Tone Berge present new insights into immune-cell processes in MS through evaluate dysregulation af CD4+ and CD8+ cells from MS patients.

DNA-variationer ved multipel sklerose 

Vi fandt, at der ikke var signifikant sammenhæng mellem MS og mtDNA-variationerne G15927A eller G15928A. Det tidligere studie med 100 tyske MS-patienter viste, at mtDNA-variationerne G15927A eller G15928A forekom hos 14% af alle MS-patienterne og hos 2% af kontrolpersonerne.6 Således har de to studier modstridende resultater.

Smoking, air pollution and MS

Hear the latest data on the association between smoking and an increased risk of MS. There are several interesting new data.

Adverse events with fatal outcome

Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.

Highlights from ECTRIMS

Melinda Magyari, Head of the Danish MS Registry, gives in this MEdtalk some of her highlights from the ECTRIMS Congress.